Roger Stein: A bold new way to fund drug research
Rodžer Stajn (Roger Stein): Odvažan novi način finansiranja istraživanja za lekove
Roger Stein wants to bring financial engineering to the world of drug funding. Full bio
Double-click the English transcript below to play the video.
Mnogi su tada pušili.
that actually touches everybody.
u Sjedinjenim Američkim Državama,
about a one in three chance
jedan prema tri
da učestvuje u testiranju
drugim ljudima poput mog oca,
we think about raising money
način prikupljanja novca
for Financial Engineering at MIT,
za finansijski inženjering na MIT,
his own bits of research,
proračunima i analizama,
something we could do.
ili Dejvid Fegnan -
how to make a cancer drug.
leka protiv raka.
iz osnova da promeni način
of other things gets done.
kao i mnoge druge stvari.
upravljaju finansiranjem,
iz laboratorije,
the drug to healthy people
da li će se razboleti od njega.
toliko ozbiljna
neće biti vredan toga?
to see if the drug's effective,
testira se efektivnost leka,
give it to people with cancer
test it on a very large sample,
na veoma velikom uzorku,
is what the right dose is, and also,
come out the other side.
zapravo izađe na tržište.
te plave bočice spasavaju živote,
jednokratno,
you have one of the blue ones.
da li je to jedna od ovih plavih.
o njima kao o lekovima?
them as financial assets?"
o njima kao o finansijskim sredstvima?
structures and all that,
but in order to make it work,
ali ne mogu da nađu finansije.
called the Valley of Death
you can't get to the later stages.
ne možete stići do kasnijih faza.
do recimo, 150 lekova
but now we need a lot of capital,
ali nam treba veliki kapital,
Philanthropies don't have it.
Filantropi ga nemaju.
get people in the capital markets,
finansijski inženjering.
a next phase of approval,
možete da prodate,
kamatu na obveznice,
fund the next round of trials.
za sledeću fazu testiranja.
i pričali smo o tome malo,
hajde da zaista pokušamo s testiranjem.
smo proveli istražujući.
za finansiranje lekova
koji su razvijali lekove.
koji su odobreni, odbijeni
otkrili smo nešto iznenađujuće.
strukturisati taj fond
obveznice s malim rizikom,
about five to eight percent,
od oko pet do osam procenata
obezbedio povrat od 12%.
about a 12-percent return.
who want to make those big bets
koji žele da ulažu mnogo
that would be interested in that.
dosta drugih ljudi koje to interesuje.
in the academic press.
u akademskim časopisima.
u medicinskim zbornicima.
u finansijskim zbornicima.
od toga da ovo predočimo ljudima.
just make people aware of it, though.
took all of our computer code
i vidite da li ovo funkcioniše.
to see if this would work.
and see how it would work.
da vide da li one rade.
the world to fund this stuff?
da se ovo isfinansira?
sa fiksnim prihodom.
more than just money that's required.
više od novca.
da ih uključimo
people to get involved,
o svemu što bi moglo da krene po zlu.
the different things that could go wrong.
this that might get in the way?
koji bi mogli da se ispreče?
različite delove ovog problema,
rad na kreditnom riziku?
a work stream on credit risk?
on the regulatory aspects?
sa toliko projekata?
the summer, this past summer.
Američko društvo protiv raka
that we thought would be important,
za koja smo mislili da su bitna,
and heard the reports
and they talked about it.
obično postoji večera,
it was the summertime --
da li to može i da se ostvari.
od ovih istraživanja.
sa našim penzionim planovima,
da finansiramo stotine istraživanja
ABOUT THE SPEAKER
Roger Stein - Financial management expertRoger Stein wants to bring financial engineering to the world of drug funding.
Why you should listen
Roger Stein is a senior lecturer in finance at MIT's Sloan School of Management and a research affiliate at the MIT Laboratory for Financial Engineering. He is also the former chief analytics officer at State Street Global Exchange. He has been working in risk modeling and financial prediction for almost 25 years; his products and services are used widely in industry and have become benchmarks in banking and finance. With MIT colleagues, he is currently collaborating on a new model that uses modern risk management methods and financial engineering techniques to change the way new drug research is funded.
Previously he was managing director of research and academic relations globally for Moody’s Corporation, and prior to that was president of Moody’s Research Labs. He has a Ph.D. from New York University, has coauthored two full-length texts on applied analytics, and has written more than 50 academic articles and papers. He has also been practicing Aikido since 1980.
Roger Stein | Speaker | TED.com